Éric Levy

1.6k total citations
34 papers, 1.1k citations indexed

About

Éric Levy is a scholar working on Oncology, Cancer Research and Pathology and Forensic Medicine. According to data from OpenAlex, Éric Levy has authored 34 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 11 papers in Cancer Research and 9 papers in Pathology and Forensic Medicine. Recurrent topics in Éric Levy's work include Cancer Immunotherapy and Biomarkers (7 papers), Immunotherapy and Immune Responses (6 papers) and Cancer Genomics and Diagnostics (5 papers). Éric Levy is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), Immunotherapy and Immune Responses (6 papers) and Cancer Genomics and Diagnostics (5 papers). Éric Levy collaborates with scholars based in France, United States and United Kingdom. Éric Levy's co-authors include Stéphane Oudard, Eugéniu Banu, Jean‐Marie Andrieu, Éric Tartour, Pascal Piedbois, Elias Haddad, J.P. Le Bourgeois, H. Frikha, Isabelle Sarfati and Raquel F. D. van la Parra and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Éric Levy

32 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Éric Levy France 17 509 279 220 203 161 34 1.1k
Tadashi Hongyo Japan 18 689 1.4× 246 0.9× 364 1.7× 85 0.4× 91 0.6× 43 1.4k
Chiara Menin Italy 19 606 1.2× 166 0.6× 475 2.2× 64 0.3× 164 1.0× 66 1.2k
Naotaka Shibagaki Japan 16 278 0.5× 372 1.3× 362 1.6× 124 0.6× 109 0.7× 42 920
Atsushi Wakita Japan 15 295 0.6× 408 1.5× 329 1.5× 86 0.4× 103 0.6× 53 1.2k
Evelyn Nguyen United States 16 282 0.6× 1.3k 4.5× 241 1.1× 283 1.4× 70 0.4× 20 1.9k
Ángel Pizarro Spain 16 407 0.8× 83 0.3× 829 3.8× 197 1.0× 132 0.8× 52 1.3k
Masakatsu Hishizawa Japan 20 542 1.1× 758 2.7× 413 1.9× 52 0.3× 171 1.1× 70 1.6k
John Williams United States 20 366 0.7× 82 0.3× 355 1.6× 81 0.4× 141 0.9× 41 1.1k
David H. Dreyfus United States 20 429 0.8× 374 1.3× 171 0.8× 131 0.6× 280 1.7× 45 1.5k
Françoise Bonnet France 14 244 0.5× 59 0.2× 294 1.3× 123 0.6× 82 0.5× 31 769

Countries citing papers authored by Éric Levy

Since Specialization
Citations

This map shows the geographic impact of Éric Levy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Éric Levy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Éric Levy more than expected).

Fields of papers citing papers by Éric Levy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Éric Levy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Éric Levy. The network helps show where Éric Levy may publish in the future.

Co-authorship network of co-authors of Éric Levy

This figure shows the co-authorship network connecting the top 25 collaborators of Éric Levy. A scholar is included among the top collaborators of Éric Levy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Éric Levy. Éric Levy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pyke, Rachel Marty, Dattatreya Mellacheruvu, Charles W. Abbott, et al.. (2022). A machine learning algorithm with subclonal sensitivity reveals widespread pan-cancer human leukocyte antigen loss of heterozygosity. Nature Communications. 13(1). 1925–1925. 18 indexed citations
2.
Abbott, Charles W., Sean M. Boyle, Rachel Marty Pyke, et al.. (2021). Prediction of Immunotherapy Response in Melanoma through Combined Modeling of Neoantigen Burden and Immune-Related Resistance Mechanisms. Clinical Cancer Research. 27(15). 4265–4276. 35 indexed citations
3.
Parra, Raquel F. D. van la, Krishna B. Clough, Helene Thygesen, et al.. (2021). Oncological Safety of Oncoplastic Level II Mammoplasties After Neoadjuvant Chemotherapy for Large Breast Cancers: A Matched-Cohort Analysis. Annals of Surgical Oncology. 28(11). 5920–5928. 20 indexed citations
4.
Kim, Jihoon, Chisato Shimizu, Stephen F. Kingsmore, et al.. (2017). Whole genome sequencing of an African American family highlights toll like receptor 6 variants in Kawasaki disease susceptibility. PLoS ONE. 12(2). e0170977–e0170977. 13 indexed citations
5.
Levy, Éric, Rachel Marty, Brian Woo, et al.. (2016). Immune DNA signature of T-cell infiltration in breast tumor exomes. Scientific Reports. 6(1). 30064–30064. 24 indexed citations
6.
Saddawi‐Konefka, Robert, Ruth Seelige, Emilie Gross, et al.. (2016). Nrf2 Induces IL-17D to Mediate Tumor and Virus Surveillance. Cell Reports. 16(9). 2348–2358. 96 indexed citations
7.
Sork, Victoria L., et al.. (2016). Landscape genomic analysis of candidate genes for climate adaptation in a California endemic oak, Quercus lobata. American Journal of Botany. 103(1). 33–46. 82 indexed citations
8.
Lévy, Pierre, Joseph Gligorov, Martine Antoine, et al.. (2013). Influence of ABCB1 polymorphisms and docetaxel pharmacokinetics on pathological response to neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Research and Treatment. 139(2). 421–428. 17 indexed citations
9.
Médioni, Jacques, Cyrille Huchon, Marie‐Aude Le Frère‐Belda, et al.. (2011). Neoadjuvant Dose-Dense Gemcitabine plus Docetaxel and Vinorelbine plus Epirubicin for Operable Breast Cancer. Drugs in R&D. 11(2). 147–157. 7 indexed citations
10.
Oudard, Stéphane, Eugéniu Banu, Jacques Médioni, et al.. (2009). What is the real impact of bone pain on survival in patients with metastatic hormone‐refractory prostate cancer treated with docetaxel?. British Journal of Urology. 103(12). 1641–1646. 27 indexed citations
11.
Ramlau, Rodryg, Élisabeth Quoix, Janusz Rolski, et al.. (2008). A Phase II Study of Tg4010 (Mva-Muc1-Il2) in Association with Chemotherapy in Patients with Stage III/IV Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 3(7). 735–744. 162 indexed citations
12.
Scotté, Florian, Eugéniu Banu, Jacques Médioni, et al.. (2008). Matched case‐control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel‐induced onycholysis and cutaneous toxicity of the foot. Cancer. 112(7). 1625–1631. 67 indexed citations
13.
Gligorov, Joseph, Frédèric Selle, Éric Levy, et al.. (2007). ABCB1 (MDR1) genotype in relation to doxorubicin and docetaxel pharmacokinetics in patients with breast cancer. Cancer Research. 67. 729–729. 1 indexed citations
14.
Banu, Eugéniu, Adela Banu, Jacques Médioni, et al.. (2007). Serum PSA half‐life as a predictor of survival for hormone‐refractory prostate cancer patients: Modelization using a standardized set of response criteria. The Prostate. 67(14). 1543–1549. 10 indexed citations
15.
Kolesnikov-Gauthier, H., Éric Levy, André Syrota, et al.. (2005). FDG PET in patients with cancer of an unknown primary. Nuclear Medicine Communications. 26(12). 1059–1066. 25 indexed citations
16.
Claret, Emmanuel, John Wijdenes, Hans Yssel, et al.. (2003). A Fluorospot assay to detect single T lymphocytes simultaneously producing multiple cytokines. Journal of Immunological Methods. 283(1-2). 91–98. 83 indexed citations
17.
Ray‐Coquard, Isabelle, Thomas Bachelot, Jean‐Paul Guastalla, et al.. (2003). Epirubicin and paclitaxel (EPI-TAX regimen) for advanced ovarian cancer after failure of platinum-containing regimens. Gynecologic Oncology. 88(3). 351–357. 7 indexed citations
18.
Kirova, Youlia, Elias Haddad, Éric Levy, et al.. (1999). Radiotherapy in the management of mycosis fungoides: indications, results, prognosis. Twenty years experience. Radiotherapy and Oncology. 51(2). 147–151. 18 indexed citations
19.
Kirova, Youlia, Ernest Bélembaogo, H. Frikha, et al.. (1998). Radiotherapy in the management of epidemic Kaposi's sarcoma: a retrospective study of 643 cases. Radiotherapy and Oncology. 46(1). 19–22. 56 indexed citations
20.
Piedbois, Pascal, H. Frikha, Laurent Martin, et al.. (1994). Radiotherapy in the management of epidemic Kaposi's sarcoma. International Journal of Radiation Oncology*Biology*Physics. 30(5). 1207–1211. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tadashi Hongyo Breakdown of academic impact, for papers by Chiara Menin Breakdown of academic impact, for papers by Naotaka Shibagaki Breakdown of academic impact, for papers by Atsushi Wakita Breakdown of academic impact, for papers by Evelyn Nguyen Breakdown of academic impact, for papers by Ángel Pizarro Breakdown of academic impact, for papers by Masakatsu Hishizawa Breakdown of academic impact, for papers by John Williams Breakdown of academic impact, for papers by David H. Dreyfus Breakdown of academic impact, for papers by Françoise Bonnet
Rankless by CCL
2026